<DOC>
	<DOCNO>NCT01149668</DOCNO>
	<brief_summary>The purpose study determine long-term ( &gt; 6 month ) safety PCI 24781 PO subject lymphoma .</brief_summary>
	<brief_title>A Safety Tolerability Study PCI-24781 Subjects With Cancer</brief_title>
	<detailed_description>An open-label , monotherapy , multicenter , extension study open subject derive benefit PCI 24781 PO least 6 month want continue receive study drug . Subjects enrol study receive PCI-24781 schedule dosage prior protocol . Treatment may continue long evidence progressive disease unacceptable toxicity .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<mesh_term>Abexinostat</mesh_term>
	<criteria>1 . Men woman cancer progress treat PCI 24781 PO least 6 month want continue receive study drug 2 . Eastern Cooperative Oncology Group ( ECOG ) performance status â‰¤ 2 3 . Agreement use contraception study 30 day last dose study drug sexually active able bear child 4 . Willing able participate require evaluation procedure study protocol include swallow capsule without difficulty 5 . Ability understand purpose risk study provide sign date informed consent authorization use protect health information ( accordance national local subject privacy regulation ) 1 . A lifethreatening illness , medical condition organ system dysfunction , investigator 's opinion , could compromise subject 's safety , interfere absorption metabolism oral PCI24781 , put study outcome undue risk 2 . Significant cardiovascular disease uncontrolled symptomatic arrhythmia , congestive heart failure , myocardial infarction within 6 month screen , Class 3 4 cardiac disease define New York Heart Association Functional Classification 3 . Malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel ulcerative colitis , symptomatic inflammatory bowel disease , partial complete bowel obstruction 4 . Immunotherapy , chemotherapy , radiotherapy , corticosteroid ( dosage equivalent prednisone &gt; 20 mg/day ) experimental therapy ( PCI24781 PO ) within 4 week first dose study drug 5 . Concomitant use medicine know cause QT prolongation torsades de point ( see Appendix 2 ) 6 . Central nervous system involvement lymphoma 7 . Known history Human Immunodeficiency Virus ( HIV ) active infection Hepatitis C Virus ( HCV ) Hepatitis B Virus ( HBV ) uncontrolled active systemic infection 8 . Creatinine &gt; 1.5 x institutional upper limit normal ( ULN ) ; total bilirubin &gt; 1.5 x ULN ( unless due Gilbert 's disease ) ; aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2.5 x ULN 9 . Lactating pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>PCI-24781</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Non-Hodgkin 's</keyword>
	<keyword>Hodgkin Disease</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Lymphocytic</keyword>
	<keyword>Chronic</keyword>
</DOC>